Neurogene Inc. (NGNE) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -121.35M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 88.50M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-121.35M | (m) | (m) | $88.50M | (m) | (m) |
| 2026-03-31 | $-110.76M | (m) | (m) | $82.40M | (m) | (m) |
| 2025-12-31 | $-103.33M | $0.00 | (m) | $75.01M | (m) | (m) |
| 2025-09-30 | $-97.31M | $0.00 | (m) | $69.72M | (m) | (m) |
| 2025-06-30 | $-95.69M | $0.00 | (m) | $68.76M | (m) | (m) |
| 2025-03-31 | $-89.75M | (m) | (m) | $65.14M | (m) | (m) |
| 2024-12-31 | $-82.61M | $925.00K | (m) | $60.92M | (m) | -8930.27% |
| 2024-09-30 | $-75.83M | (m) | (m) | $57.75M | (m) | (m) |
| 2024-06-30 | $-68.86M | (m) | (m) | $53.08M | (m) | (m) |
| 2024-03-31 | $-61.33M | (m) | (m) | $47.65M | (m) | (m) |
| 2023-12-31 | $-55.58M | (m) | (m) | $44.39M | (m) | (m) |
| 2023-09-30 | $-38.02M | (m) | (m) | $17.88M | (m) | (m) |
| 2023-06-30 | $-46.06M | (m) | (m) | $26.74M | (m) | (m) |
| 2023-03-31 | $-58.87M | (m) | (m) | $38.12M | (m) | (m) |
| 2022-12-31 | $-59.10M | (m) | (m) | $41.13M | (m) | (m) |
| 2022-09-30 | $-60.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-61.86M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-61.12M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-60.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-58.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-44.96M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-39.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-33.73M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-29.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-86.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-70.96M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $-67.90M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-23.58M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-32.62M | $25.00M | (m) | $41.79M | (m) | -130.50% |
| 2018-09-30 | (m) | (m) | (m) | $50.78M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | $48.52M | (m) | (m) |
| 2017-12-31 | $-51.12M | (m) | (m) | $36.27M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | $32.84M | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | $30.52M | (m) | (m) |
| 2016-12-31 | $-37.65M | (m) | (m) | $28.38M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |